Helicobacter pylori Biofilm-Related Drug Resistance and New Developments in Its Anti-Biofilm Agents
Chong Hou,Fangxu Yin,Song Wang,Ailing Zhao,Yingzi Li,Yipin Liu
DOI: https://doi.org/10.2147/IDR.S357473
2022-04-05
Infection and Drug Resistance
Abstract:Chong Hou, 1, &ast Fangxu Yin, 2, &ast Song Wang, 2 Ailing Zhao, 1 Yingzi Li, 1 Yipin Liu 1 1 Department of Gastroenterology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, 264100, People's Republic of China; 2 Department of Thyroid and Breast Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, 256603, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yipin Liu, Department of Gastroenterology, Yantai Affiliated Hospital of Binzhou Medical University, No. 717 Jinbu Street, Muping District, Yantai, Shandong, 264100, People's Republic of China, Tel +86-18953595711, Email Helicobacter pylori is one of the most common pathogenic bacterium worldwide, infecting about 50% of the world's population. It is a major cause of several upper gastrointestinal diseases, including peptic ulcers and gastric cancer. The emergence of H. pylori resistance to antibiotics has been a major clinical challenge in the field of gastroenterology. In the course of H. pylori infection, some bacteria invade the gastric epithelium and are encapsulated into a self-produced matrix to form biofilms that protect the bacteria from external threats. Bacteria with biofilm structures can be up to 1000 times more resistant to antibiotics than planktonic bacteria. This implies that targeting biofilms might be an effective strategy to alleviate H. pylori drug resistance. Therefore, it is important to develop drugs that can eliminate or disperse biofilms. In recent years, anti-biofilm agents have been investigated as alternative or complementary therapies to antibiotics to reduce the rate of drug resistance. This article discusses the formation of H. pylori biofilms, the relationship between biofilms and drug resistance in H. pylori , and the recent developments in the research of anti-biofilm agents targeting H. pylori drug resistance. Keywords: Helicobacter pylori , biofilm, biofilm formation, anti-biofilm molecules, antibiotic resistance, resistance mechanism Helicobacter pylori is a Gram-negative microaerobic spiral rod-shaped bacterium that was first cultured and identified by Professors Marshall and Dr. Warren. 1 This bacterium primarily colonizes the gastric mucosal surface and has been linked to chronic gastritis, peptic ulcer, gastric mucosa-associated tissue lymphoma (MALT), gastric cancer, and other upper gastrointestinal disorders. 2 Standard triple therapy (proton pump inhibitor + two antibiotics) and bismuth quadruple therapy (proton pump inhibitor + bismuth + two antibiotics) are the most commonly used during eradication therapies for H. pylori . 3 H. pylori secrete proteins, polysaccharides, extracellular DNA (eDNA), and other molecules to create extracellular polymeric substances (EPS) after colonizing the gastric mucosa, which are wrapped and adhered to each other by bacteria to form biofilms. 4 Unlike planktonic bacteria, colonies that form biofilm structures are highly resistant to the harsh external environment, including antibiotic exposure. 5 It is well established that when bacteria develop biofilms, their resistance to antibiotics increases by up to 10–1000 times. 6 Therefore, the formation of H. pylori biofilms is most likely the primary cause of long-term chronic infection, multiple drug resistance, and treatment failure. Consequently, strategies targeting biofilms can be applied to alleviate H. pylori drug resistance. Research should be directed at developing anti-biofilm agents/molecules and determine their minimum effective concentration that can completely eradicate biofilm with maximum potency without causing unwanted side effects to the host. The formation of H. pylori biofilms decreases efficacy of conventional eradication treatments. 7 Individual planktonic bacteria which grow on agar plates or broths are often used as platforms for antibiotic susceptibility testing. However, these bacteria do not exist as independent individuals, and the majority do not live as a single species. 8 About 80% of the world's bacteria are known to exist as biofilms, 9 and this has been their major means of survival for billions of years. 10 Bacteria that form biofilms adhere to one another using extracellular polymeric substances (EPS) composed of polysaccharides, proteins, extracellular DNA (eDNA), and share information using quorum sensing (QS) system, allowing them to live in an organized manner similar to that of animal populations. 4 In the event of a threat, such as drastic changes in temper -Abstract Truncated-
pharmacology & pharmacy,infectious diseases